GILD
GILEAD SCIENCES, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 6 to May 15 ▲ 2 buys: Jared Moskowitz, Ro Khanna bought, last disclosed Jun 22
- Jul 21 ▼ Leerink Partners downgrades
- Aug 20 to Sep 1 ▼ 3 days of insider sells: $5.3M by 3 insiders, avg $148.29
- Sep 15 ▼ 2 insiders sell $868.5K at $144.75
- Sep 17 Trial readout: Results Pending: Filgotinib (Phase 3), Completed 9d ago
- Sep 30 ▲ 4 funds open new positions (13F)
- Oct 1 ▼ 1 insider sell $2.2M at $147.90
- Oct 14 Cash v. Gilead Sciences Inc. et al
- Oct 15 ▼ 2 insiders sell $937.3K at $156.22
- Oct 17 Trial readout: Results Pending: Filgotinib (Phase 3), Completed 39d ago
- Oct 29 ▲ Gilead reported Q3 2026 product sales of $8.3B (+13% YoY) and non-GA…
- Oct 30 to Nov 6 ▼ 5 days of insider sells: $25.6M by 2 insiders, avg $174.36
- Nov 12 New insider trade: subscribers see the details Unlock
- Nov 13 New legal action: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersMIXED
6 insiders sold $34.9M. Excludes 4 subscriber-only trades.
- InstitutionsMIXED
Q3 2026: 51 added (4 new), 45 trimmed or exited. Largest new: Capital International Investors $228.5M, 1832 Asset Management $114.8M.
- AnalystsBULLISH
30 of 36 rate it Buy or better.
- Short sellersSTEADY
Short interest +4.9% to 21.27M shares. 3.2 days to cover, ≈1.7% of shares.
- TrendUPTREND
8% above its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 30.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | ADD | $1.8B |
| DEUTSCHE BANK AG\ | ADD | $1.4B |
| UBS Group AG | TRIM | $486.5M |
| BARCLAYS PLC | TRIM | $468.2M |
| Swedbank AB | ADD | $428.5M |
| Assenagon Asset Management S.A. | TRIM | $232.6M |
| Capital International Investors | NEW | $228.5M |
| ProShare Advisors LLC | TRIM | $215.2M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
36 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 16, 2026 | 🔒 Fresh data, subscribers only MAINTAIN | |
| Oct 30, 2026 | UBS MAINTAIN | Buy |
| Oct 30, 2026 | JP Morgan MAINTAIN | Overweight |
| Oct 30, 2026 | Citigroup MAINTAIN | Buy |
| Oct 30, 2026 | Scotiabank MAINTAIN | Sector Outperform |
| Oct 30, 2026 | TD Cowen MAINTAIN | Buy |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
| 🔒 Fresh data, subscribers only Nov 12, 2026 | SELL | |
| 🔒 Fresh data, subscribers only Nov 12, 2026 | EXERCISE | |
| 🔒 Fresh data, subscribers only Nov 12, 2026 | SELL | |
| 🔒 Fresh data, subscribers only Nov 12, 2026 | SELL | |
| 🔒 Fresh data, subscribers only Nov 12, 2026 | SELL | |
Cain Wettan Keeley M EVP Gen Counsel, Legal & Comp Nov 6, 2026 | SELL | $557.8K |
O'Day Daniel Patrick Chairman & CEO Nov 5, 2026 | SELL | $1.7M |
O'Day Daniel Patrick Chairman & CEO Nov 5, 2026 | EXERCISE | $709.7K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
30 filings · 6 bullish · 3 bearish · 21 neutral- NEUTRAL 144Nov 16, 2026
Andrew D. Dickinson, an officer of Gilead Sciences, filed a Form 144 notice of intent to sell 3,000 shares of common stock with an approximate market value of $514,410. The shares were acquired as performance shares on January 31, 2024.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL CLUSTERNov 16, 2026
Two GILD insiders, including the CEO, executed open-market sales totaling $2.28M under 10b5-1 plans. The CEO's $1.72M sale is the largest, but both sales are pre-planned and represent a trivial 0.001% of the company's $208.3B market cap, making them routine portfolio diversification with no…
🔒 Fresh report (last 24h), subscribers only
- BULLISH COURT-RULINGNov 13, 2026
Gilead Sciences obtained a default judgment in its Eastern District of New York case against multiple defendants for counterfeit drug trafficking. The court entered total damages of approximately $52.1 million and a permanent injunction against the defaulting defendants.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 144Nov 12, 2026
Director Kelly Kramer filed a Form 144 notice of intent to sell 10,376 shares of Gilead Sciences…
This is a routine Form 144 filing by a director. The sale amount is small relative to Gilead's market cap. No material impact expected. Monitor for any subsequent Form 4 filings to confirm execution.
All GILD filing & press-release reports (30)
- 144 reportNov 16, 2026
- CLUSTER reportNov 16, 2026
- COURT-RULING reportNov 13, 2026
- 144 reportNov 12, 2026
- CLUSTER reportNov 9, 2026
- 144 reportNov 6, 2026
- 144 reportNov 4, 2026
- 144 reportOct 30, 2026
- 8-K reportOct 29, 2026
- INST-CLUSTER reportOct 22, 2026
- CLUSTER reportOct 16, 2026
- COURT-RULING reportOct 14, 2026
- CLUSTER reportSep 16, 2026
- CLUSTER reportSep 16, 2026
- CLUSTER reportSep 2, 2026
- CLUSTER reportAug 27, 2026
- CLUSTER reportAug 21, 2026
- COURT-RULING reportAug 18, 2026
- CLUSTER reportAug 18, 2026
- COURT-RULING reportAug 13, 2026
- S-3ASR reportAug 6, 2026
- Leerink Partners downgrades GILD to Market Perform, PT $127 (-4.7%)Jul 21, 2026
- CLUSTER reportJul 16, 2026
- HSBC upgrades GILD to Buy, PT $155 (+18%)Jul 6, 2026
- CLUSTER reportJun 16, 2026
- Maxim Group upgrades GILD to Buy, PT $165 (+26.4%)May 20, 2026
- 424B5 reportMay 18, 2026
- 424B5 reportMay 14, 2026
- CLUSTER reportApr 15, 2026
- DEFA14A reportMar 20, 2026